Shots:

• Kaken to receive an up front in cash and is eligible to receive milestones and royalties on the sales of the product. Almirall plans to have a pre-submission meeting with regulatory authorities in next year to prepare the approval of the product in the EU
• Almirall get the exclusive rights for the development and commercialization of the topical antifungal formulation of efinaconazole in the EU
• Efinaconazole is a triazole antifungal therapy indicated for the treatment of fungal infection of the nail called onychomycosis

  | Ref: PR Newswire | Image: PR Newswire